Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised, double-blind, placebo-controlled study of opicapone 50 mg in Parkinson's disease patients with end-of-dose motor fluctuations and pain
2020-001175-32Phase 4Unknown
- Sponsor
- BIAL
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Parkinson's disease (PD) comparing Opicapone 50 mg with Placebo (2 arms). Primary endpoint: Change from baseline in KPPS Domain 3 (fluctuation-related pain). Status: unknown.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2020-001175-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001175-32.